Trial-Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)

• Global Clinical Dementia Rating score of 0 or 0.5 and no diagnosis of dementia
• Study partner who is willing to participate as a source of information and has at least weekly contact (in-person, via telephone, or electronic communication) with the participant
• Good general health
• Adequate visual and auditory ability to allow neuropsychological testing
• Fluent in English or Spanish
• Females who are not surgically sterile or postmenopausal for 2 years must receive a negative pregnancy test prior to amyloid PET scan
• Completed six grades of education or has a good work history
• Evidence of elevated or intermediate levels of brain amyloid, as assessed by amyloid PET or cerebrospinal fluid data; prior amyloid testing results may be used with approval from the Coordinating Center

• Treatment with another anti-amyloid investigational drug or other intervention within past 12 months
• Enrolled in another interventional clinical trial within the last 12 weeks
• Any significant neurological disease such as Alzheimer's disease dementia, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma
• Major depression, bipolar disorder, agitation or behavioral problems within the past 3 months that could lead to difficulty complying with the study; history of schizophrenia
• History of alcohol or substance abuse or dependence within the past 2 years
• Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease
• History within the last 3 years of a primary or recurrent malignant disease, with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment
• Clinically significant abnormalities in vitamin B12 or thyroid function tests
• Clinically significant abnormalities in laboratory tests or electrocardiogram
• For participants undergoing cerebrospinal fluid collection, current blood clotting or bleeding disorder

University of Southern California

• National Institute on Aging (NIA)
• Alzheimer's Therapeutic Research Institute
• Alzheimer's Clinical Trials Consortium
• Brigham and Women's Hospital
• Cleveland Clinic Lou Ruvo Center for Brain Health